{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:27:03Z","timestamp":1790033223644,"version":"4.0.1"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272656"],"award-info":[{"award-number":["82272656"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260502"],"award-info":[{"award-number":["82260502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.critrevonc.2026.105186","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:03:36Z","timestamp":1770253416000},"page":"105186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies"],"prefix":"10.1016","volume":"220","author":[{"given":"Xiaoli","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105186_bib1","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"Biomed. Pharm. Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib2","article-title":"Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives","volume":"59","author":"Ahmed","year":"2019","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib3","article-title":"Marine peptides in breast cancer: Therapeutic and mechanistic understanding","volume":"142","author":"Ahmed","year":"2021","journal-title":"Biomed. Pharm. Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105186_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105186_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105186_bib8","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","article-title":"Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib9","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized Phase II Study of the Anti\u2013Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001492","article-title":"Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer","volume":"10","author":"Batra","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.critrevonc.2026.105186_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-011-1352-2","article-title":"Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial","volume":"126","author":"Bernsdorf","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105186_bib12","first-page":"1027","article-title":"EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Bhargava","year":"2005","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2026.105186_bib13","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1021\/acs.molpharmaceut.3c00715","article-title":"Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice","volume":"20","author":"Biali","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccell.2018.06.006","article-title":"Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development","volume":"34","author":"Binder","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105186_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4161\/cbt.11.9.15050","article-title":"Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab","volume":"11","author":"Brand","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105186_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress","volume":"13","author":"Budi","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.critrevonc.2026.105186_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2850","article-title":"Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice","volume":"13","author":"Burga","year":"2011","journal-title":"Breast Cancer Res. BCR"},{"key":"10.1016\/j.critrevonc.2026.105186_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The Advantages of Targeted Protein Degradation over Inhibition: a RTK Case Study","volume":"25","author":"Burslem","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib19","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s12079-023-00771-w","article-title":"Role of EGFR and FASN in breast cancer progression","volume":"17","author":"Chaturvedi","year":"2023","journal-title":"J. Cell Commun. Signal"},{"key":"10.1016\/j.critrevonc.2026.105186_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115911","article-title":"Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques","volume":"262","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105186_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1158\/2159-8290.CD-19-0463","article-title":"Histone Lysine Methylation Dynamics Control EGFR DNA Copy Number Amplification","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105186_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"PROTAC 2.0: Expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105186_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00373-3","volume":"16","author":"Cort\u00e9s","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2026.105186_bib25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/15384047.2015.1026481","article-title":"A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer","volume":"16","author":"Cowherd","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105186_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2015.08.002","article-title":"N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and\/or taxane-containing therapy","volume":"16","author":"Crozier","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib27","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/0008-5472.CAN-11-2656","article-title":"Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma","volume":"72","author":"Del Vecchio","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10637-007-9055-6","article-title":"A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer","volume":"25","author":"Dennison","year":"2007","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105186_bib29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","article-title":"Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients","volume":"23","author":"DiGiovanna","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105186_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib32","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1158\/0008-5472.CAN-17-3370","article-title":"The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer","volume":"78","author":"El Kadi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105186_bib34","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1158\/0008-5472.CAN-20-2773","article-title":"EGFR Activates a TAZ-driven Oncogenic Program in Glioblastoma","volume":"81","author":"Gao","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/annonc\/mdl322","article-title":"EGFR mutations in exons 18-21 in sporadic breast cancer","volume":"18","author":"Generali","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib36","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/1947601911407325","article-title":"PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control","volume":"1","author":"Georgescu","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib37","first-page":"131","article-title":"Potential of afatinib in the treatment of patients with HER2-positive breast cancer","volume":"4","author":"Geuna","year":"2012","journal-title":"Breast Cancer Targets Ther."},{"key":"10.1016\/j.critrevonc.2026.105186_bib38","doi-asserted-by":"crossref","unstructured":"Gioiello, L., Di Martino, R.M.C., Pirali, T., n.d. Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery. J. Med. Chem. 68, 23676\u201323689. \u3008https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01911\u3009.","DOI":"10.1021\/acs.jmedchem.5c01911"},{"key":"10.1016\/j.critrevonc.2026.105186_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105186_bib40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdp202","article-title":"Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer","volume":"20","author":"Green","year":"2009","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105186_bib42","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.critrevonc.2026.105186_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10020-023-00736-0","article-title":"Neratinib for HER2-positive breast cancer with an overlooked option","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105186_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/ijo.2022.5468","article-title":"Upregulation of the EGFR\/MEK1\/MAPK1\/2 signaling axis as a mechanism of resistance to antiestrogen-induced BimEL dependent apoptosis in ER+ breast cancer cells","volume":"62","author":"Hagan","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00540-9","article-title":"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial","volume":"17","author":"Harbeck","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2026.105186_bib46","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.3390\/cells11213416","article-title":"The Role of the Epidermal Growth Factor Receptor in Diabetic Kidney Disease","volume":"11","author":"Harris","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105186_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib48","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/s41467-024-45594-4","article-title":"Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants","volume":"15","author":"Hayes","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105186_bib49","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/s41388-019-0817-3","article-title":"The miR-186-3p\/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells","volume":"38","author":"He","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105186_bib50","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1158\/1078-0432.CCR-09-0520","article-title":"Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer","volume":"15","author":"Horn","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105186_bib51","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.critrevonc.2026.105186_bib52","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ijc.32191","article-title":"EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies","volume":"145","author":"Jia","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib53","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12943-024-02150-4","article-title":"Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR","volume":"23","author":"Kang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib55","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1158\/0008-5472.CAN-07-1013","article-title":"Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1","volume":"67","author":"Lahusen","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.2014.556","article-title":"Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer","volume":"112","author":"Lee","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib57","doi-asserted-by":"crossref","first-page":"a020768","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib58","first-page":"688","article-title":"Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade","volume":"10","author":"Li","year":"2020","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib59","article-title":"Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Lo Nigro","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105186_bib62","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.3390\/ijms241914777","article-title":"Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer","volume":"24","author":"L\u00f3pez-Mej\u00eda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105186_bib63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105186_bib64","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41422-022-00628-8","article-title":"EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription","volume":"32","author":"Lu","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib65","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2015.01.009","article-title":"CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines","volume":"87","author":"Maeda","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25257-4","article-title":"Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides","volume":"12","author":"Mansour","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105186_bib67","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of Epidermal Growth Factor Receptor in Breast Cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105186_bib68","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamaoncol.2018.1436","article-title":"Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer","volume":"4","author":"Matsuda","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib69","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1158\/1078-0432.CCR-04-1923","article-title":"A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer","volume":"11","author":"Miller","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105186_bib70","article-title":"Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer","volume":"115","author":"Mn","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105186_bib71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"Morabito","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105186_bib72","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdu183","article-title":"Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline\/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact","volume":"25","author":"Nabholtz","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib73","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105186_bib74","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2026.105186_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046614","article-title":"Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells","volume":"7","author":"Nowsheen","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2026.105186_bib76","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"New EMBO members\u2019 review","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2026.105186_bib77","first-page":"5094","article-title":"Conflicting roles of EGFR expression by subtypes in breast cancer","volume":"11","author":"Oshi","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105186_bib78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib79","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimization Trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2353\/jmoldx.2008.070125","article-title":"Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry","volume":"10","author":"Pinter","year":"2008","journal-title":"J. Mol. Diagn. JMD"},{"key":"10.1016\/j.critrevonc.2026.105186_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2011.02.024","article-title":"CXCR4 Suppression Attenuates EGFRvIII-Mediated Invasion and Induces p38 MAPK-Dependent Protein Trafficking and Degradation of EGFRvIII in Breast Cancer Cells","volume":"306","author":"Rahimi","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105186_bib82","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/jcph.496","article-title":"Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer","volume":"55","author":"Rodr\u00edguez-Vera","year":"2015","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib83","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-World Perspectives and Practices for Pneumonitis\/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2\u2013Expressing Metastatic Breast Cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol. Pr."},{"key":"10.1016\/j.critrevonc.2026.105186_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115536","article-title":"Expressing IL-15\/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer","volume":"212","author":"Ruixin","year":"2023","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib85","first-page":"22","article-title":"Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer","volume":"7","author":"Saleh","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.critrevonc.2026.105186_bib86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","article-title":"Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor\u2013Positive Metastatic Breast Cancer","volume":"15","author":"Schwartzberg","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105186_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.critrevonc.2026.105186_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cells13010047","article-title":"Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications","volume":"13","author":"Shaban","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105186_bib89","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1634\/theoncologist.2010-0012","article-title":"Quality of Life in Hormone Receptor\u2013Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib","volume":"15","author":"Sherrill","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105186_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.09.6578","article-title":"A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer","volume":"25","author":"Smith","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib91","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2174\/1574892818666221201145810","article-title":"Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer","volume":"18","author":"Sun","year":"2023","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105186_bib92","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib Suppresses MDSC Recruitment via SDF1\u03b1\/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105186_bib93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdm444","article-title":"Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment","volume":"19","author":"Tan","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib94","first-page":"3081","article-title":"Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer","volume":"60","author":"Tang","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105186_bib95","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2857","article-title":"Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy","volume":"13","author":"Teng","year":"2011","journal-title":"Breast Cancer Res. BCR"},{"key":"10.1016\/j.critrevonc.2026.105186_bib96","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1677\/JME-07-0165","article-title":"Phosphorylation at serines 104 and 106 by Erk1\/2 MAPK is important for estrogen receptor-\u03b1 activity","volume":"40","author":"Thomas","year":"2008","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clbc.2014.07.007","article-title":"Ixabepilone alone or with cetuximab as first-line treatment for advanced\/metastatic triple-negative breast cancer","volume":"15","author":"Tr\u00e9dan","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib98","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.seminoncol.2014.08.003","article-title":"Tumor antigen-specific monoclonal antibodies and induction of T cell immunity","volume":"41","author":"Trivedi","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib99","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2015.10.012","article-title":"A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)","volume":"53","author":"Tryfonidis","year":"2016","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2026.105186_bib100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejca.2007.12.011","article-title":"Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study","volume":"44","author":"Twelves","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105186_bib102","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2017.75.9175","article-title":"Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)","volume":"36","author":"Untch","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.prp.2011.03.002","article-title":"Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy","volume":"207","author":"Uribe","year":"2011","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.critrevonc.2026.105186_bib104","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/biomedicines11030661","article-title":"Regulation of ErbB Receptors by the Ca2+ Sensor Protein Calmodulin in Cancer","volume":"11","author":"Villalobo","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105186_bib105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-004-1720-2","article-title":"A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer","volume":"89","author":"von Minckwitz","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105186_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127440","article-title":"Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review","volume":"253","author":"Wang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib107","article-title":"Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24\/Siglec-10 Signaling Pathway","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105186_bib108","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s13277-012-0324-4","article-title":"Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells","volume":"33","author":"Wang","year":"2012","journal-title":"Tumor Biol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib109","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/sj.bjc.6602557","article-title":"Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors","volume":"92","author":"Weber","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(05)70176-5","article-title":"Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial","volume":"6","author":"Polychronis","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2026.105186_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105186_bib112","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.critrevonc.2026.105186_bib113","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12885-021-08150-7","article-title":"The expression and prognostic value of the epidermal growth factor receptor family in glioma","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105186_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1446414","article-title":"HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105186_bib115","doi-asserted-by":"crossref","unstructured":"Yang, J.L., Yamada-Hunter, S.A., Labanieh, L., Sotillo, E., Cheah, J.S., Roberts, D.S., Mackall, C.L., Bertozzi, C.R., Ting, A.Y., n.d. Directed evolution of genetically encoded LYTACs for cell-mediated delivery. Proc. Natl. Acad. Sci. U. S. A. 121, e2320053121. \u3008https:\/\/doi.org\/10.1073\/pnas.2320053121\u3009.","DOI":"10.1073\/pnas.2320053121"},{"key":"10.1016\/j.critrevonc.2026.105186_bib116","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/mt.2012.184","article-title":"Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses","volume":"21","author":"Yang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105186_bib117","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2017.06.001","article-title":"Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer","volume":"489","author":"Yang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105186_bib118","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.870395","article-title":"The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy","volume":"9","author":"Yuan","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105186_bib120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsmedchemlett.1c00645","article-title":"Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19\/T790M\/C797S Mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.critrevonc.2026.105186_bib121","article-title":"Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.critrevonc.2026.105186_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.608","article-title":"Epidermal growth factor receptor\u2011targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real-world study","volume":"5","author":"Zhang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.critrevonc.2026.105186_bib123","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/pharmrev.123.000906","article-title":"Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor","volume":"75","author":"Zhang","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105186_bib124","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antib10010007","article-title":"Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers","volume":"10","author":"Zhao","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/j.critrevonc.2026.105186_bib125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cancers16010006","article-title":"Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors","volume":"16","author":"Zheng","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105186_bib126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acscentsci.1c00146","article-title":"Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins","volume":"7","author":"Zhou","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.critrevonc.2026.105186_bib127","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41401-024-01232-9","article-title":"Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities","volume":"45","author":"Zhou","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.critrevonc.2026.105186_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1270407","article-title":"Research progress of cancer cell membrane coated nanoparticles for the diagnosis and therapy of breast cancer","volume":"13","author":"Zhou","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13058-023-01728-y","article-title":"Single-cell transcriptomics provide insight into metastasis-related subsets of breast cancer","volume":"25","author":"Zhu","year":"2023","journal-title":"Breast Cancer Res. BCR"},{"key":"10.1016\/j.critrevonc.2026.105186_bib130","article-title":"Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib131","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.3390\/cancers15164164","article-title":"Advancing Breast Cancer Heterogeneity Analysis: Insights from Genomics, Transcriptomics and Proteomics at Bulk and Single-Cell Levels","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105186_bib132","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cancers16040800","article-title":"Next-Generation HER2-Targeted Antibody\u2013Drug Conjugates in Breast Cancer","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105186_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1381970","article-title":"Targeting metabolism of breast cancer and its implications in T cell immunotherapy","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105186_bib134","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:18:32Z","timestamp":1777605512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":134,"alternative-id":["S1040842826000739"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105186","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105186"}}